ClinicaliQ Trial Snapshot
- A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD1043 in Healthy Adult Participants Living With Overweight and/or Obesity. — Recruiting • Phase I • Diabetes / Metabolic • NCT07511205.
- A new weight loss drug (AZD1043) is being tested for safety and effectiveness in overweight and obese adults.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of the study is to assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of AZD1043 following single and multiple ascending doses in healthy adult participants living with overweight and/or obesity, including participants of Japanese and Chinese descent. Conditions: Healthy Participants, Obesity Interventions: AZD1043, Placebo Lead Sponsor: AstraZeneca Planned Enrollment: 104 participants